S-23 is a selective androgen receptor modulator (SARM) that has been researched for its potential in muscle growth, bone health, and potentially as a treatment for conditions like osteoporosis and muscle wasting. SARMs like S-23 are designed to selectively bind to androgen receptors in the body, affecting them in a way that promotes muscle and bone growth while minimizing some of the unwanted side effects associated with anabolic steroids.

In preclinical studies, S-23 has shown anabolic (muscle-building) effects and an ability to increase bone mineral density. It’s been suggested that S-23 might have a higher affinity for androgen receptors in muscle and bone tissue compared to other tissues, potentially leading to fewer side effects associated with androgens.

However, it’s important to note that the research on S-23 is still in its early stages, primarily conducted on animals. There’s limited data available on its safety and efficacy in humans. As with other SARMs and similar compounds, there are concerns about potential adverse effects and long-term safety that haven’t been fully understood or studied.

Due to the lack of comprehensive human trials and regulatory approval, using S-23 or any similar compound comes with risks, and its use should only be considered under the guidance and supervision of a qualified healthcare professional.